China-based Shanghai Henlius Biotech Inc (2696.HK) and Accord Healthcare Limited, a subsidiary of Intas Pharmaceuticals Ltd, have received approval from the European Commission (EC) for their Zercepac, a biosimilar, trastuzumab, intended for the treatment of certain patients with HER2-positive early breast cancer, HER2-positive metastatic breast cancer and earlier untreated HER2-positive metastatic gastric cancer, it was reported on Wednesday.
The product received approval based on a series of studies including comparative quality studies, preclinical and clinical studies.
Zercepac was developed and produced by Henlius and is the first monoclonal antibody (mAb) and third biosimilar, launched by Accord in Europe, and is the first mAb developed by Henlius to be approved in the European Union.
Rx-360 partners with Leucine to offer access to regulatory intelligence platform
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
Active Biotech to receive US patent for tasquinimod formulation
Sanofi and Regeneron's Dupixent approved in EU for chronic spontaneous urticaria
Clearmind Medicine advances global CMND-100 AUD trial with first patient enrolled in Israel
NeuroSense's PrimeC receives FDA clearance for pivotal Phase 3 trial in ALS
Made Scientific enters manufacturing partnership with Cellergy Therapeutics
Novartis' Itvisma granted US FDA approval for spinal muscular atrophy treatment
Avidity Biosciences announces US Managed Access Program for delpacibart zotadirsen (del-zota)
Nuvalent's zidesamtinib NDA filing accepted by US FDA
Mycovia Pharmaceuticals publishes long-term efficacy results from extension study of VIVJOA
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
AbbVie receives approval for EPKINLY, rituximab and lenalidomide combination